ArticleFrontiers in neurology2025
Cladribine tablets as therapy for advanced relapsing-remitting multiple sclerosis: a 4-year follow-up real-world, multi-center, retrospective, cohort study.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-World, Long-Term Outcomes with Cladribine Tablets Versus Other Oral Treatments Among Patients with Multiple Sclerosis.Neurology and therapy · 2026Article
- Assessment of brain atrophy as a promising marker of radiological activity in patients with relapsing-remitting multiple sclerosis.Frontiers in neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cladribine tablets (CladT) are a high-efficacy disease-modifying therapy recommended for the treatment of relapsing-remitting multiple sclerosis (RRMS) particularly in early disease. This study is aimed to evaluate the long-term efficacy of CladT in population of Polish RRMS patients, with more advanced disease. Methods: This retrospective observational study included patients with RRMS who started CladT treatment between December 2019 and November 2023. Collected data included prior treatments, annualized relapse rate (ARR), magnetic resonance imaging (MRI) activity, Expanded Disability Status Scale (EDSS) score, no evidence of disease activity (NEDA-3), lymphocyte counts, and safety outcomes were collected. Results: Of the 230 patients (8.3% treatment-naïve, mean disease duration 9.2 years), follow-up data were available up to year 1 for 222 patients, year 2 for 154 patients, year 3 for 87 patients and year 4 for 31 patients. The ARR decreased from 1.42 at baseline to 0.26, 0.22, and 0.36 in years 1, 2, and 3, respectively. The proportion of relapse-free patients increased from 13.9% at baseline to 76.8% in year 1, 82% in year 2 and 75.4% in year 3 with no relapses reported in year 4. The proportion of patients with active MRI lesions declined from 90.4% at baseline to 36.3% in year 1, 25.2% in year 2, 45.9% in year 3 and 8.3% in year 4. Stable or improved EDSS was observed in 85.9% of patients in year 1, 80.8% in year 2, 73.7% in year 3 and 88.9% in year 4. NEDA-3 status was achieved in 47.4% of patients in year 1, 51.0% in year 2, 40.4% in year 3 and 71.4% in year 4. Adverse events were reported in 16.7% of patients in years 1-2 and in 6.3% of patients in year 3. Discussion: The results indicate that CladT is effective and safe in Polish patients with RRMS, characterized by high disease activity, delayed treatment initiation, and multiple number of prior therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.